June 11, 2018 09:12 AM EDTUpdated 09:59 AM

Bitterly opposed old guard at Takeda wages a last-ditch fight to block 'foreign blood's' $62B Shire buyout

Amber Tong

As Takeda CEO Christophe Weber pulls the strings for director support in the $62 billion acquisition of Shire, a small group of ex-Takeda employees have …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bitterly opposed old guard at Takeda wages a last-ditch fight to block 'foreign blood's' $62B Shire buyout

Amber Tong

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Bit­ter­ly op­posed old guard at Take­da wages a last-ditch fight to block 'for­eign blood­'s' $62B Shire buy­out

Amber Tong

Sign up to read this article for free.

more like this

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Bitterly opposed old guard at Takeda wages a last-ditch fight to block 'foreign blood's' $62B Shire buyout

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role